Want to see SNTI full AI Analyst Report?
SNTI Stock Chart & Stats
$1.10
-$0.36(-8.15%)
At close: 4:00 PM EST
$1.10
-$0.36(-8.15%)
Day’s Range― - ―
52-Week Range$0.42 - $2.88
Previous CloseN/A
Volume20.15K
Average Volume (3M)286.64K
Market Cap
$13.61M
Enterprise Value$35.20M
Total Cash (Recent Filing)$8.94M
Total Debt (Recent Filing)$19.14M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding31,144,754
10 Day Avg. Volume525,728
30 Day Avg. Volume286,643
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)41.84
Price to Sales (P/S)10628.51
P/FCF Ratio-5.36
Enterprise Value/Market Cap2.59
Enterprise Value/Revenue926.40
Enterprise Value/Gross Profit-10.88
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$12.00Price Target Upside990.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$38.67K
Bulls Say, Bears Say
Bulls Say
Platform & DifferentiationSenti's engineered cell platform uses programmable gene circuits to control activation, persistence and safety in cell therapies. This modular, platform-driven approach is durable: it supports multiple indications, enables partner licensing and creates technical barriers to entry versus single-product competitors.
Regulatory Pathway SupportClear FDA feedback and RMAT/Orphan designations materially reduce regulatory uncertainty for SENTI-202, enabling a defined registration path. This structural clarity can shorten development timelines and improve commercial viability if the pivotal trial succeeds, sustaining program value over months.
Clinical Signal & Manufacturing ProgressDurable MRD‑negative responses and a 50% composite CR in Phase 1 provide an early efficacy signal; incorporating Donor X attributes into manufacturing reflects CMC learning. These outcomes strengthen the likelihood of reproducible clinical performance and practical scale-up for future trials or partners.
Bears Say
Weak Financial PerformancePersistent minimal revenue and large recurring losses drive continuous cash burn, forcing reliance on external financing. This structural operating deficit constrains R&D pacing and makes long-term program funding contingent on capital markets or partners, increasing execution and dilution risk.
Fragile Balance SheetHigh leverage and a shrunken asset base leave a thin equity cushion against setbacks. Creditors hold priority and limited capital flexibility raises the probability that operational hiccups or trial delays lead to difficult refinancing or unfavorable transaction terms, reducing strategic optionality.
Convertible Notes & Dilution/Governance RiskThe secured convertible notes extend runway but carry harsh terms: short maturity, steep cash payoff on non-conversion and full‑ratchet anti‑dilution. These provisions can force significant dilution or creditor control if milestones slip, creating structural governance and shareholder value risks over the medium term.
Senti Biosciences News
SNTI FAQ
What was Senti Biosciences, Inc.’s price range in the past 12 months?
Senti Biosciences, Inc. lowest stock price was $0.42 and its highest was $2.88 in the past 12 months.
What is Senti Biosciences, Inc.’s market cap?
Senti Biosciences, Inc.’s market cap is $13.61M.
When is Senti Biosciences, Inc.’s upcoming earnings report date?
Senti Biosciences, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 29 days.
How were Senti Biosciences, Inc.’s earnings last quarter?
Senti Biosciences, Inc. released its earnings results on May 14, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.14.
Is Senti Biosciences, Inc. overvalued?
According to Wall Street analysts Senti Biosciences, Inc.’s price is currently Undervalued.
Does Senti Biosciences, Inc. pay dividends?
Senti Biosciences, Inc. does not currently pay dividends.
What is Senti Biosciences, Inc.’s EPS estimate?
Senti Biosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senti Biosciences, Inc. have?
Senti Biosciences, Inc. has 31,144,754 shares outstanding.
What happened to Senti Biosciences, Inc.’s price movement after its last earnings report?
Senti Biosciences, Inc. reported an EPS of -$0.14 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.996%.
Which hedge fund is a major shareholder of Senti Biosciences, Inc.?
Currently, no hedge funds are holding shares in SNTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senti Biosciences, Inc.
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
SNTI Stock 12 Month Forecast
Average Price Target
$12.00
▲(990.91% Upside)
Technical Analysis
Plus Therapeutics
―
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
―
Ownership Overview
2.63% Insiders
0.46% Mutual Funds
― Other Institutional Investors
95.18% Public Companies and
Individual Investors